Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Single Center Retrospective Evaluation of CHOP-Based Regimens in Older Patients with Treatment Naïve Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN).

Created on 16 Nov 2026

Authors

Casey Fealko, Charles Foucar, Nhi TranHuynh, Lydia L Benitez, Anthony Perissinotti, Bernard L Marini, Naveen Pemmaraju, Dale L Bixby

Published in

Acta haematologica. Nov 16, 2026. Epub Nov 16, 2026.

Abstract

Blastic plasmacytoid dendritic cell neoplasm (BPCDN) is an extremely rare and aggressive hematologic malignancy. Several chemotherapeutic approaches have been described as induction strategies for BPDCN. The approval of tagraxofusp-erzs, a CD123-directed cytotoxin, for treatment naïve or relapsed/refractory BPDCN was based on a single-arm phase II study, but many patients may not qualify for this therapy due to hypoalbuminemia or other co-morbidities. Optimal treatment remains under investigation, especially for older and unfit patients, with allogenic hematopoietic stem cell transplant (allo-HCT) being the only potentially curable treatment option available. We report the clinical outcomes of a single center, retrospective analysis of patients with treatment naïve BPDCN treated with CHOP-based induction regimens. Of the 12 patients treated, 92% (11 out of 12) achieved a partial response. 50% (6 out of 12) achieved CR or CRi after induction therapy. Of those patients, 4 received hematopoietic stem cell transplant (HCT) with 3 receiving allo-HCTs and 1 receiving an auto-HCT. Mean overall survival rate for the entire cohort was 16.4 months (95% CI 12.8 - 20). For those who received HCT, overall survival was 27.8 months (95% CI 9.8 - 48.8). The major driver in improvement in overall survival difference appears to be younger age and ability to proceed to allo-HCT. Although limited by retrospective design and small number of patients, this study suggests CHOP-based induction strategies achieve remission rates similar to those obtained with tagraxofusp-erzs for treatment naïve BPDCN and may be considered as a potential frontline therapy for older patients with BPDCN.

PMID:
43037508
Bibliographic data and abstract were imported from PubMed on 16 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 10
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement